WALTHAM, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced that research on the use of VIVITROL® (naltrexone for extended-release injectable suspension) in the treatment of alcohol and opioid dependence will be presented at the American Society of Addiction Medicine’s (ASAM) 42nd Annual Medical-Scientific Conference. The ASAM Medical-Scientific Conference takes place April 14 through 17, 2011 in Washington, D.C.
